Premium
Achieving cancer cell death with PI3K/mTOR‐targeted therapies
Author(s) -
Yea Sung Su,
Fruman David A.
Publication year - 2013
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/nyas.12028
Subject(s) - pi3k/akt/mtor pathway , discovery and development of mtor inhibitors , cancer , medicine , cancer research , rptor , signal transduction , biology , microbiology and biotechnology
Inhibitors of the PI3K/mTOR signaling network are under development as novel cancer therapies. However, these compounds do not cause robust cytotoxic responses in tumor cells unless combined with other agents. Rational combinations with other targeted therapies will likely be necessary to achieve the potential of PI3K/mTOR inhibitors in oncology.